DARE: Dare Bioscience Inc. Stocks News on June 2, 2025

DARE

Thomson Reuters StreetEvents

19 days ago

Q1 2025 Dare Bioscience Inc Earnings Call

DARE

GuruFocus.com

19 days ago

Dare Bioscience Inc (DARE) Q1 2025 Earnings Call Highlights: Strategic Expansions and Cost ...

DARE

Zacks

20 days ago

Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

DARE

GlobeNewswire

20 days ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

DARE

GlobeNewswire

a month ago

Daré Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

DARE

GlobeNewswire

a month ago

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

DARE

GlobeNewswire

2 months ago

Daré Bioscience to Present at the Jones Healthcare and Technology Innovation Conference on Expanded Business Strategy Including Action to Make its Proprietary Sildenafil Cream Formulation Available via Prescription This Year

DARE

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Dare Bioscience Inc Earnings Call

DARE

GuruFocus.com

2 months ago

Dare Bioscience Inc (DARE) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ...

DARE

Zacks

2 months ago

Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

DARE

GlobeNewswire

2 months ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

DARE

GlobeNewswire

2 months ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

DARE

GlobeNewswire

3 months ago

Daré Bioscience and Theramex Announce Co-Development and Licensing Agreement for a Potential Biodegradable Long-Acting Contraceptive Implant

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

DARE

GlobeNewswire

4 months ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

DARE

GlobeNewswire

5 months ago

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

DARE

MT Newswires

6 months ago

Dare Bioscience to Submit Plan for Phase 3 Study of Potential Female Sexual Disorder Treatment

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

DARE

GlobeNewswire

6 months ago

Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD)

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

DARE

GlobeNewswire

6 months ago

Daré Bioscience Announces Publication in Sexual Medicine of Positive Findings from Demographic, Behavioral and Medication Use Subgroup Analyses in the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

DARE

GlobeNewswire

6 months ago

Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

DARE

Thomson Reuters StreetEvents

7 months ago

Q3 2024 Dare Bioscience Inc Earnings Call

DARE

GuruFocus.com

7 months ago

Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...

DARE

Zacks

7 months ago

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

DARE

GlobeNewswire

7 months ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

DARE

GlobeNewswire

7 months ago

Daré Bioscience Announces Grant to Support Development of a Novel Non-Hormonal Contraceptive Candidate and Expansion of Ovaprene® Pivotal Study Clinical Trial Sites

DARE

Zacks

7 months ago

Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

DARE

GlobeNewswire

7 months ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?

DARE

Zacks

7 months ago

Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year?

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

DARE

GlobeNewswire

7 months ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H’s Sprint for Women’s Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

DARE

GlobeNewswire

7 months ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

DARE

GlobeNewswire

9 months ago

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

DARE

GlobeNewswire

10 months ago

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%

DARE

Zacks

10 months ago

Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

DARE

GlobeNewswire

10 months ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024

DARE

GlobeNewswire

10 months ago

Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024

DARE

MT Newswires

10 months ago

Dare Bioscience Regains Nasdaq Compliance

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

DARE

GlobeNewswire

10 months ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

DARE

MT Newswires

a year ago

Dare Bioscience to Implement 1-for-12 Reverse Stock Split

Daré Bioscience Announces Reverse Stock Split

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder

DARE

Thomson Reuters StreetEvents

a year ago

Q1 2024 Dare Bioscience Inc Earnings Call

DARE

GuruFocus.com

a year ago

Dare Bioscience Inc (DARE) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves Amid ...

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

DARE

GlobeNewswire

a year ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

DARE

GlobeNewswire

a year ago

Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

DARE

GlobeNewswire

a year ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

DARE

GlobeNewswire

a year ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

DARE

Insider Monkey

a year ago

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript

DARE

Thomson Reuters StreetEvents

a year ago

Q4 2023 Dare Bioscience Inc Earnings Call

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

DARE

GlobeNewswire

a year ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

DARE

GlobeNewswire

a year ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

DARE

GlobeNewswire

a year ago

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Comcast (CMCSA) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

DARE

Zacks

a year ago

Comcast (CMCSA) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

Vision Sensing Acquisition Corp. Received Nasdaq Delisting Determination Letter and Intends to Appeal the Determination and Request a Stay Pending the Appeal Hearing

DARE

GlobeNewswire

a year ago

Vision Sensing Acquisition Corp. Received Nasdaq Delisting Determination Letter and Intends to Appeal the Determination and Request a Stay Pending the Appeal Hearing

Shareholders in Lake Shore Bancorp (NASDAQ:LSBK) are in the red if they invested five years ago

DARE

Simply Wall St.

a year ago

Shareholders in Lake Shore Bancorp (NASDAQ:LSBK) are in the red if they invested five years ago

AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

DARE

Zacks

a year ago

AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal

We Think Allied Gaming & Entertainment (NASDAQ:AGAE) Can Afford To Drive Business Growth

DARE

Simply Wall St.

a year ago

We Think Allied Gaming & Entertainment (NASDAQ:AGAE) Can Afford To Drive Business Growth

Nine Energy Service Announces Timing of Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

DARE

Business Wire

a year ago

Nine Energy Service Announces Timing of Fourth Quarter and Full Year 2023 Earnings Release and Conference Call

Red Cat to Participate in the 2024 SHOT Show

DARE

GlobeNewswire

a year ago

Red Cat to Participate in the 2024 SHOT Show

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DARE

Business Wire

a year ago

Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

EMCORE Corporation Enters Into Cooperation Agreement with Bradley L. Radoff

DARE

GlobeNewswire

a year ago

EMCORE Corporation Enters Into Cooperation Agreement with Bradley L. Radoff

Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream

DARE

GlobeNewswire

a year ago

Presenting on Emerging Growth Conference 66 Day 2 on January 11 Register to Stream

Hurco Companies Full Year 2023 Earnings: EPS: US$0.67 (vs US$1.24 in FY 2022)

DARE

Simply Wall St.

a year ago

Hurco Companies Full Year 2023 Earnings: EPS: US$0.67 (vs US$1.24 in FY 2022)

CervoMed to Participate in the Emerging Growth Conference 66

DARE

GlobeNewswire

a year ago

CervoMed to Participate in the Emerging Growth Conference 66

DARE

GlobeNewswire

a year ago

Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases

DARE

Simply Wall St.

a year ago

When Will Daré Bioscience, Inc. (NASDAQ:DARE) Become Profitable?

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

DARE

GlobeNewswire

a year ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Loop Media Accesses Capital and Reduces Prior Existing Debt

DARE

Business Wire

a year ago

Loop Media Accesses Capital and Reduces Prior Existing Debt

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

DARE

GlobeNewswire

a year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Skillz Inc. (SKLZ) Shows Fast-paced Momentum But Is Still a Bargain Stock

DARE

Zacks

a year ago

Skillz Inc. (SKLZ) Shows Fast-paced Momentum But Is Still a Bargain Stock

$ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)$

DARE

GlobeNewswire

a year ago

ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

DARE

GlobeNewswire

a year ago

BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

Insider Buying: SuRo Capital Corp's Mark Klein Acquires 49,885 Shares

DARE

GuruFocus.com

a year ago

Insider Buying: SuRo Capital Corp's Mark Klein Acquires 49,885 Shares

DARE

Thomson Reuters StreetEvents

a year ago

Q3 2024 Vera Bradley Inc Earnings Call

Vera Bradley Inc (VRA) Reports Mixed Third Quarter Fiscal 2024 Results Amidst Market Challenges

DARE

GuruFocus.com

a year ago

Vera Bradley Inc (VRA) Reports Mixed Third Quarter Fiscal 2024 Results Amidst Market Challenges

DARE

GlobeNewswire

2 years ago

Cumulus Podcast Network to Provide Brand Safety & Suitability Measurement Through Barometer

Shareholders in Lee Enterprises (NASDAQ:LEE) are in the red if they invested five years ago

DARE

Simply Wall St.

2 years ago

Shareholders in Lee Enterprises (NASDAQ:LEE) are in the red if they invested five years ago

HeartBeam, Inc. (NASDAQ:BEAT) Q3 2023 Earnings Call Transcript

DARE

Insider Monkey

2 years ago

HeartBeam, Inc. (NASDAQ:BEAT) Q3 2023 Earnings Call Transcript

Wish Further Expands its Logistics as a Service (LaaS) Arm with the Launch of ‘WishPost Smart Parcel’

DARE

GlobeNewswire

2 years ago

Wish Further Expands its Logistics as a Service (LaaS) Arm with the Launch of ‘WishPost Smart Parcel’

Fossil Group, Inc. (NASDAQ:FOSL) Q3 2023 Earnings Call Transcript

DARE

Insider Monkey

2 years ago

Fossil Group, Inc. (NASDAQ:FOSL) Q3 2023 Earnings Call Transcript

Farmer Bros. Co. (NASDAQ:FARM) Q1 2024 Earnings Call Transcript

DARE

Insider Monkey

2 years ago

Farmer Bros. Co. (NASDAQ:FARM) Q1 2024 Earnings Call Transcript

Strong week for DZS (NASDAQ:DZSI) shareholders doesn't alleviate pain of five-year loss

DARE

Simply Wall St.

2 years ago

Strong week for DZS (NASDAQ:DZSI) shareholders doesn't alleviate pain of five-year loss

Bright Health Group, Inc. (NYSE:BHG) Q3 2023 Earnings Call Transcript

DARE

Insider Monkey

2 years ago

Bright Health Group, Inc. (NYSE:BHG) Q3 2023 Earnings Call Transcript

DARE

Zacks Small Cap Research

2 years ago

PLX: More Regulatory Approvals

DARE

Associated Press Finance

2 years ago

Viant: Q3 Earnings Snapshot

DARE

Business Wire

2 years ago

Viant Technology Announces Third Quarter 2023 Financial Results

Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results

DARE

GuruFocus.com

2 years ago

Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results

Bogota Financial Corp. Reports Results for the Three and Nine Months Ended September 30, 2023

DARE

Business Wire

2 years ago

Bogota Financial Corp. Reports Results for the Three and Nine Months Ended September 30, 2023

DARE

Thomson Reuters StreetEvents

2 years ago

Q3 2023 Westwood Holdings Group Inc Earnings Call

DARE

GuruFocus.com

2 years ago

Westwood Holdings Group Inc (WHG) Reports Q3 2023 Earnings: Revenues and Net Income Rise

Westwood Holdings Group, Inc. Reports Third Quarter 2023 Results

DARE

GlobeNewswire

2 years ago

Latest Dare Bioscience Inc. (DARE) News on June 2, 2025

Share on Social Networks: